Revium Rx (RVRC) Other Non-Current Liabilities (2025 - 2026)
Revium Rx's (RVRC) quarterly Other Non-Current Liabilities came in at $575000.0 in Q2 2026, little changed quarter-over-quarter from $575000.0 in Q4 2025.
Powered by 
Analysis
Revium Rx (RVRC) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends
Revium Rx has disclosed Other Non-Current Liabilities across 2 years of filings, most recently posting $575000.0 for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities changed N/A year-over-year to $575000.0; the TTM figure through Jun 2026 stood at $575000.0 (changed N/A YoY), while the FY2025 annual figure was $575000.0, changed N/A from the prior year.
- Other Non-Current Liabilities came in at $575000.0 for Q2 2026 at Revium Rx, roughly flat from $575000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $575000.0 in Q4 2025 to a low of $575000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Revium Rx | 86.84 Mn | 85.34 Mn | - |